274. 骨形成不全症 Disease details / Clinical trials / Drug dev / DR info

Aclasta
   Bente Langdahl, consultant, ass. professor, PhD, DMSc
      2011   Phase 2   EUCTR2011-002811-27-DK   Denmark
   Schriners Hospitals for Children
      2012   Phase 3   EUCTR2011-000745-21-BE   Belgium;Canada;United States
Actonel 5MG film coated tablets
   Sheffield Children's NHS Foundation Trust
      2017   Phase 2   EUCTR2016-003606-14-GB   United Kingdom
Actonel once A week 35 MG FILM-coated tablets
   Sheffield Children's NHS Foundation Trust
      2017   Phase 2   EUCTR2016-003606-14-GB   United Kingdom
Actonel/optinate 5MG FILM-coated tablets
   Procter & Gamble Ltd
      2006   -   EUCTR2004-000485-13-FI   Czech Republic;Denmark;Finland;Hungary;Spain
AGA2115
   Angitia Incorporated Limited
      2023   Phase 1   NCT06086613   United States
Alendronate
   Indiana University School of Medicine
      1999   Phase 4   NCT00159419   United States
   Ito Nobuaki
      2023   Phase 2   JPRN-jRCTs031220726   -
   Peking Union Medical College Hospital
      2007   Phase 4   NCT02303873   -
   Tohoku University School of Medicine, Department of Pediatrics
      2013   -   JPRN-UMIN000010615   Japan
Alendronic acid
   University of Edinburgh
      2022   Phase 4   EUCTR2016-003228-22-DK   Denmark;Ireland;Netherlands;United Kingdom
      2021   Phase 4   EUCTR2016-003228-22-NL   Denmark;France;Ireland;Netherlands;United Kingdom
      2017   Phase 4   EUCTR2016-003228-22-IE   Denmark;Ireland;Netherlands;United Kingdom
      2016   Phase 4   EUCTR2016-003228-22-GB   Denmark;France;Ireland;Netherlands;United Kingdom
Alternative osteoporosis medications
   Amgen
      2018   Phase 3   NCT03638128   Australia;Belgium;Canada;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
AMG 162
   AMGEN INC.
      2019   Phase 3   EUCTR2018-000550-21-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2014-000184-40-IT   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
   Amgen Inc
      2020   Phase 3   EUCTR2018-000550-21-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-000550-21-CZ   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-000550-21-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000550-21-GB   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000550-21-ES   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000550-21-PL   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000550-21-HU   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2018-000550-21-FR   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2018-000550-21-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
   Amgen Inc.
      2015   Phase 3   EUCTR2014-000184-40-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      -   -   EUCTR2014-000184-40-Outside-EU/EEA   Australia;Canada;United States
   Amgen, Inc.
      2020   Phase 3   EUCTR2014-000184-40-PL   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-000184-40-GB   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000184-40-HU   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000184-40-ES   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000184-40-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000184-40-CZ   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Hungary;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2014-000184-40-FR   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2014-000184-40-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
AMG 785
   AMGEN INC.
      2020   Phase 1   EUCTR2017-004972-74-IT   Austria;France;Germany;Greece;Hungary;Italy;Spain;Turkey
   Amgen Inc.
      2021   Phase 1   EUCTR2017-004972-74-GR   Austria;France;Germany;Greece;Hungary;Italy;Spain;Turkey
      2021   Phase 1   EUCTR2017-004972-74-DE   France;Germany;Greece;Hungary;Italy;Spain;Turkey
      2020   Phase 1   EUCTR2017-004972-74-HU   France;Germany;Greece;Hungary;Italy;Spain;Turkey
      -   Phase 1   EUCTR2017-004972-74-AT   Austria;Germany;Greece;Hungary;Italy;Spain;Turkey;United States
ANTI-sclerostin monoclonal antibody
   Mereo BioPharma 3 Ltd.
      2017   Phase 2   EUCTR2016-005096-27-DK   Canada;Denmark;France;United Kingdom;United States
   Mereo Biopharma 3 Ltd.
      2017   Phase 2   EUCTR2016-005096-27-GB   Canada;Denmark;France;United Kingdom;United States
      2017   Phase 2   EUCTR2016-005096-27-FR   Canada;Denmark;France;United Kingdom;United States
   Novartis Pharma Services AG
      2012   -   EUCTR2011-001465-41-DE   Canada;Germany
      2011   Phase 1;Phase 2   EUCTR2011-001465-41-BE   Belgium;Canada;Germany
Bisphosphonate
   Amgen
      2024   Phase 3   NCT05972551   Australia;Austria;Belgium;Canada;France;Germany;Hungary;Japan;Poland;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
   Asato Keita
      2024   Phase 3   JPRN-jRCT2061230103   Australia;Austria;Belgium;Canada;France;Germany;Hungary;Japan;Poland;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
   Ultragenyx Pharmaceutical Inc
      2023   Phase 3   NCT05768854   Brazil;Canada;France;Germany;Italy;Netherlands;Poland;United States
Bisphosphonates
   Asato Keita
      2024   Phase 3   JPRN-jRCT2061230103   Australia;Austria;Belgium;Canada;France;Germany;Hungary;Japan;Poland;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
   Luca Sangiorgi
      2013   -   NCT04115774   Italy
Blood sample
   Hospices Civils de Lyon
      2019   -   NCT04009733   France
Bone marrow cell transplantation
   St. Jude Children's Research Hospital
      1995   Phase 1   NCT00705120   United States
Bone marrow transplant
   St. Jude Children's Research Hospital
      2004   -   NCT00187018   United States
Bonefos
   University of Edinburgh
      2021   Phase 4   EUCTR2016-003228-22-NL   Denmark;France;Ireland;Netherlands;United Kingdom
      2016   Phase 4   EUCTR2016-003228-22-GB   Denmark;France;Ireland;Netherlands;United Kingdom
Boost cells
   Christian Medical College, Vellore, India
      2019   Phase 1/Phase 2   NCT04623606   India
   Karolinska Institutet
      2019   Phase 1/Phase 2   NCT03706482   Sweden
      2018   Phase 1;Phase 2   EUCTR2015-003699-60-SE   Sweden
BPS804
   Mereo BioPharma 3 Ltd.
      2017   Phase 2   EUCTR2016-005096-27-DK   Canada;Denmark;France;United Kingdom;United States
   Mereo Biopharma 3 Ltd.
      2017   Phase 2   EUCTR2016-005096-27-GB   Canada;Denmark;France;United Kingdom;United States
      2017   Phase 2   EUCTR2016-005096-27-FR   Canada;Denmark;France;United Kingdom;United States
   Novartis Pharma Services AG
      2012   -   EUCTR2011-001465-41-DE   Canada;Germany
      2011   Phase 1;Phase 2   EUCTR2011-001465-41-BE   Belgium;Canada;Germany
   Ultragenyx Pharmaceutical Inc
      2017   Phase 2   NCT03216486   United States
      2011   Phase 2   NCT01417091   Belgium;Canada;Germany;United States
   Ultragenyx Pharmaceutical Inc.
      2023   Phase 2;Phase 3   EUCTR2021-006597-23-DE   Argentina;Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Portugal;Türkiye;United Kingdom;United States
BPS804, UX143
   Ultragenyx Pharmaceutical Inc.
      2023   Phase 2;Phase 3   EUCTR2021-006597-23-PT   Argentina;Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Portugal;Türkiye;United Kingdom;United States
      2023   Phase 2;Phase 3   EUCTR2021-006597-23-PL   Argentina;Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Portugal;Türkiye;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2021-006597-23-FR   Argentina;Australia;Canada;Denmark;France;Germany;Italy;Poland;Portugal;United Kingdom;United States
Busulfan
   St. Jude Children's Research Hospital
      1995   Phase 1   NCT00705120   United States
Calcichew D3
   University of Edinburgh
      2022   Phase 4   EUCTR2016-003228-22-DK   Denmark;Ireland;Netherlands;United Kingdom
      2017   Phase 4   EUCTR2016-003228-22-IE   Denmark;Ireland;Netherlands;United Kingdom
Calcichew tablets
   Sheffield Children's NHS Foundation Trust
      2017   Phase 2   NCT03208582   United Kingdom
Calcio carbonato/colecalciferolo
   AMGEN INC.
      2020   Phase 1   EUCTR2017-004972-74-IT   Austria;France;Germany;Greece;Hungary;Italy;Spain;Turkey
Calcium
   Amgen
      2021   Phase 1   NCT04545554   Austria;Germany;Greece;Hungary;Italy;Spain;Turkey;United States
   Ultragenyx Pharmaceutical Inc
      2017   Phase 2   NCT03118570   Canada;Denmark;France;United Kingdom;United States
Calcium D3 sandoz - 1000 MG + 880 U.I. compresse effervescenti 30 compresse divisibili
   AMGEN INC.
      2020   Phase 1   EUCTR2017-004972-74-IT   Austria;France;Germany;Greece;Hungary;Italy;Spain;Turkey
Celulas madre mesenquimales troncales adultas alogenicas DE Médula óSEA NO expandida
   Itziar Astigarraga Aguirre
      2013   -   EUCTR2012-002553-38-ES   Spain
Clasteon
   University of Edinburgh
      2022   Phase 4   EUCTR2016-003228-22-DK   Denmark;Ireland;Netherlands;United Kingdom
      2017   Phase 4   EUCTR2016-003228-22-IE   Denmark;Ireland;Netherlands;United Kingdom
Cyclophosphamide
   St. Jude Children's Research Hospital
      1995   Phase 1   NCT00705120   United States
Cyclosporin
   St. Jude Children's Research Hospital
      1995   Phase 1   NCT00705120   United States
Células mesenquimales troncales adultas alogénicas DE Médula óSEA NO expandidas
   Itziar Astigarraga Aguirre
      2013   -   EUCTR2012-002553-38-ES   Spain
Denosumab
   Amgen
      2018   Phase 3   NCT03638128   Australia;Belgium;Canada;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2015   Phase 3   NCT02352753   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
   University of Cologne
      2013   Phase 2   NCT01799798   Germany
      2013   -   EUCTR2012-002887-29-DE   Germany
Denosumab - - immunoglobulin G2 human monoclonal antibody TO rank ligand
   Amgen Inc.
      -   -   EUCTR2014-000184-40-Outside-EU/EEA   Australia;Canada;United States
Denosumab - immunoglobulin G2 human monoclonal antibody TO rank ligand
   AMGEN INC.
      2019   Phase 3   EUCTR2018-000550-21-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2014-000184-40-IT   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
   Amgen Inc
      2020   Phase 3   EUCTR2018-000550-21-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-000550-21-CZ   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-000550-21-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000550-21-GB   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000550-21-ES   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000550-21-PL   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000550-21-HU   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2018-000550-21-FR   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2018-000550-21-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
   Amgen Inc.
      2015   Phase 3   EUCTR2014-000184-40-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
   Amgen, Inc.
      2020   Phase 3   EUCTR2014-000184-40-PL   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-000184-40-GB   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000184-40-HU   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000184-40-ES   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000184-40-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000184-40-CZ   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Hungary;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2014-000184-40-FR   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2014-000184-40-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
Denusomab
   University of Cologne
      2013   -   EUCTR2012-002887-29-DE   Germany
Evenity 105MG
   AMGEN INC.
      2020   Phase 1   EUCTR2017-004972-74-IT   Austria;France;Germany;Greece;Hungary;Italy;Spain;Turkey
Expanded human first trimester fetal liver-derived mesenchymal stem cells
   Karolinska Institutet
      2018   Phase 1;Phase 2   EUCTR2015-003699-60-SE   Sweden
Forsteo
   Bente Langdahl, consultant, ass. professor, PhD, DMSc
      2011   Phase 2   EUCTR2011-002811-27-DK   Denmark
Fresolimumab
   Baylor College of Medicine
      2017   Phase 1   NCT03064074   United States
Fultium-D3 800IU capsules
   University of Edinburgh
      2022   Phase 4   EUCTR2016-003228-22-DK   Denmark;Ireland;Netherlands;United Kingdom
      2017   Phase 4   EUCTR2016-003228-22-IE   Denmark;Ireland;Netherlands;United Kingdom
H05aa02
   Bente Langdahl, consultant, ass. professor, PhD, DMSc
      2011   Phase 2   EUCTR2011-002811-27-DK   Denmark
Humatrope
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1991   Phase 3   NCT00001305   United States
Ibandronic acid
   University of Edinburgh
      2022   Phase 4   EUCTR2016-003228-22-DK   Denmark;Ireland;Netherlands;United Kingdom
      2021   Phase 4   EUCTR2016-003228-22-NL   Denmark;France;Ireland;Netherlands;United Kingdom
      2017   Phase 4   EUCTR2016-003228-22-IE   Denmark;Ireland;Netherlands;United Kingdom
      2016   Phase 4   EUCTR2016-003228-22-GB   Denmark;France;Ireland;Netherlands;United Kingdom
Irradiation, total body
   St. Jude Children's Research Hospital
      1995   Phase 1   NCT00705120   United States
Mesenchymal stem cell transplantation
   St. Jude Children's Research Hospital
      1995   Phase 1   NCT00705120   United States
Mesenchymal stem cells
   Hospital de Cruces
      2014   Phase 1   NCT02172885   Spain
Mesenchymal stromal cells
   Emory University
      2025   Phase 1/Phase 2   NCT05559801   -
   Nationwide Children's Hospital
      2010   Phase 1   NCT01061099   United States
Nerixia*infus IV conc 2F 100MG
   AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
      2005   -   EUCTR2004-005275-42-IT   Italy
NO active treatment
   University of Aarhus
      2012   Phase 2   NCT01679080   Denmark
NO treatment
   Amgen
      2018   Phase 3   NCT03638128   Australia;Belgium;Canada;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
Optinate 5 MG filmcoated tablets
   Procter & Gamble Ltd
      2007   -   EUCTR2004-000485-13-DK   Czech Republic;Denmark;Finland;Hungary;Spain
Pamidronate
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      2000   Phase 3   NCT00005901   Canada;United States
   Indiana University School of Medicine
      1999   Phase 4   NCT00159419   United States
   Kobe University Hospital
      2018   -   JPRN-UMIN000031290   Japan
   University of Edinburgh
      2022   Phase 4   EUCTR2016-003228-22-DK   Denmark;Ireland;Netherlands;United Kingdom
      2021   Phase 4   EUCTR2016-003228-22-NL   Denmark;France;Ireland;Netherlands;United Kingdom
      2017   Phase 4   EUCTR2016-003228-22-IE   Denmark;Ireland;Netherlands;United Kingdom
      2016   Phase 4   EUCTR2016-003228-22-GB   Denmark;France;Ireland;Netherlands;United Kingdom
   University of New Mexico
      2007   -   NCT00655681   United States
Plasmasafe
   AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
      2015   Phase 2   EUCTR2015-002622-39-IT   Italy
Prolia
   University of Cologne
      2013   -   EUCTR2012-002887-29-DE   Germany
   University of Edinburgh
      2022   Phase 4   EUCTR2016-003228-22-DK   Denmark;Ireland;Netherlands;United Kingdom
      2021   Phase 4   EUCTR2016-003228-22-NL   Denmark;France;Ireland;Netherlands;United Kingdom
      2017   Phase 4   EUCTR2016-003228-22-IE   Denmark;Ireland;Netherlands;United Kingdom
      2016   Phase 4   EUCTR2016-003228-22-GB   Denmark;France;Ireland;Netherlands;United Kingdom
REF cruzada PEI Nº 12-088
   Itziar Astigarraga Aguirre
      2013   -   EUCTR2012-002553-38-ES   Spain
Risedronate oral tablet
   Hospital for Special Surgery, New York
      2019   Phase 4   NCT04152551   United States
Risedronate sodium
   Sheffield Children's NHS Foundation Trust
      2017   Phase 2   NCT03208582   United Kingdom
      2017   Phase 2   EUCTR2016-003606-14-GB   United Kingdom
   University of Edinburgh
      2022   Phase 4   EUCTR2016-003228-22-DK   Denmark;Ireland;Netherlands;United Kingdom
      2021   Phase 4   EUCTR2016-003228-22-NL   Denmark;France;Ireland;Netherlands;United Kingdom
      2017   Phase 4   EUCTR2016-003228-22-IE   Denmark;Ireland;Netherlands;United Kingdom
      2016   Phase 4   EUCTR2016-003228-22-GB   Denmark;France;Ireland;Netherlands;United Kingdom
   Warner Chilcott
      2004   Phase 3   NCT00106028   Australia;Belgium;Chile;Czech Republic;Finland;Germany;Hungary;Italy;Poland;South Africa;Spain;United Kingdom;United States
Risedronate sodium 2.5MG
   Procter & Gamble Ltd
      2007   -   EUCTR2004-000485-13-DK   Czech Republic;Denmark;Finland;Hungary;Spain
      2006   -   EUCTR2004-000485-13-HU   Czech Republic;Denmark;Finland;Hungary;Spain
      2006   -   EUCTR2004-000485-13-FI   Czech Republic;Denmark;Finland;Hungary;Spain
      2006   Phase 3   EUCTR2004-000485-13-CZ   Belgium;Czech Republic;Denmark;Finland;Hungary;Spain
      2006   -   EUCTR2004-000485-13-BE   Belgium;Czech Republic;Denmark;Finland;Hungary;Spain
Risedronate sodium 5MG
   Procter & Gamble Ltd
      2007   -   EUCTR2004-000485-13-DK   Czech Republic;Denmark;Finland;Hungary;Spain
      2006   -   EUCTR2004-000485-13-HU   Czech Republic;Denmark;Finland;Hungary;Spain
      2006   -   EUCTR2004-000485-13-FI   Czech Republic;Denmark;Finland;Hungary;Spain
      2006   Phase 3   EUCTR2004-000485-13-CZ   Belgium;Czech Republic;Denmark;Finland;Hungary;Spain
      2006   -   EUCTR2004-000485-13-BE   Belgium;Czech Republic;Denmark;Finland;Hungary;Spain
Risedronato Sódico 2.5MG
   Procter & Gamble Ltd
      2006   Phase 3   EUCTR2004-000485-13-ES   Belgium;Czech Republic;Denmark;Finland;Hungary;Spain
Risedronato Sódico 5MG
   Procter & Gamble Ltd
      2006   Phase 3   EUCTR2004-000485-13-ES   Belgium;Czech Republic;Denmark;Finland;Hungary;Spain
Risedronic acid
   Procter & Gamble Ltd
      2007   -   EUCTR2004-000485-13-DK   Czech Republic;Denmark;Finland;Hungary;Spain
      2006   -   EUCTR2004-000485-13-HU   Czech Republic;Denmark;Finland;Hungary;Spain
      2006   -   EUCTR2004-000485-13-FI   Czech Republic;Denmark;Finland;Hungary;Spain
      2006   Phase 3   EUCTR2004-000485-13-CZ   Belgium;Czech Republic;Denmark;Finland;Hungary;Spain
      2006   -   EUCTR2004-000485-13-BE   Belgium;Czech Republic;Denmark;Finland;Hungary;Spain
Rituximab
   Schriners Hospitals for Children
      2012   Phase 3   EUCTR2011-000745-21-BE   Belgium;Canada;United States
Romosozumab
   AMGEN INC.
      2020   Phase 1   EUCTR2017-004972-74-IT   Austria;France;Germany;Greece;Hungary;Italy;Spain;Turkey
   Amgen
      2024   Phase 3   NCT05972551   Australia;Austria;Belgium;Canada;France;Germany;Hungary;Japan;Poland;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
      2021   Phase 1   NCT04545554   Austria;Germany;Greece;Hungary;Italy;Spain;Turkey;United States
   Amgen Inc.
      2021   Phase 1   EUCTR2017-004972-74-GR   Austria;France;Germany;Greece;Hungary;Italy;Spain;Turkey
      2021   Phase 1   EUCTR2017-004972-74-DE   France;Germany;Greece;Hungary;Italy;Spain;Turkey
      2020   Phase 1   EUCTR2017-004972-74-HU   France;Germany;Greece;Hungary;Italy;Spain;Turkey
      -   Phase 1   EUCTR2017-004972-74-AT   Austria;Germany;Greece;Hungary;Italy;Spain;Turkey;United States
   Asato Keita
      2024   Phase 3   JPRN-jRCT2061230103   Australia;Austria;Belgium;Canada;France;Germany;Hungary;Japan;Poland;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
   Ito Nobuaki
      2023   Phase 2   JPRN-jRCTs031220726   -
Saline
   University of New Mexico
      2007   -   NCT00655681   United States
SAR439459
   Sanofi
      2022   Phase 1   NCT05231668   Australia;Canada;France;United States
Setrusumab
   Mereo BioPharma 3 Ltd.
      2017   Phase 2   EUCTR2016-005096-27-DK   Canada;Denmark;France;United Kingdom;United States
   Mereo Biopharma 3 Ltd.
      2017   Phase 2   EUCTR2016-005096-27-GB   Canada;Denmark;France;United Kingdom;United States
   Ultragenyx Pharmaceutical Inc
      2024   Phase 3   NCT06636071   Japan
      2023   Phase 3   NCT05768854   Brazil;Canada;France;Germany;Italy;Netherlands;Poland;United States
      2022   Phase 2   NCT05312697   United States
      2022   Phase 2/Phase 3   NCT05125809   Argentina;Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Portugal;Turkey;United Kingdom;United States
      2017   Phase 2   NCT03118570   Canada;Denmark;France;United Kingdom;United States
   Ultragenyx Pharmaceutical Inc.
      2023   Phase 2;Phase 3   EUCTR2021-006597-23-PT   Argentina;Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Portugal;Türkiye;United Kingdom;United States
      2023   Phase 2;Phase 3   EUCTR2021-006597-23-PL   Argentina;Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Portugal;Türkiye;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2021-006597-23-FR   Argentina;Australia;Canada;Denmark;France;Germany;Italy;Poland;Portugal;United Kingdom;United States
Somatropin
   AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
      2005   -   EUCTR2004-005275-42-IT   Italy
Teriparatide
   Oregon Health and Science University
      2005   Phase 4   NCT00131469   United States
   University of Aarhus
      2012   Phase 2   NCT01679080   Denmark
   University of Edinburgh
      2022   Phase 4   EUCTR2016-003228-22-DK   Denmark;Ireland;Netherlands;United Kingdom
      2021   Phase 4   EUCTR2016-003228-22-NL   Denmark;France;Ireland;Netherlands;United Kingdom
      2017   Phase 4   EUCTR2016-003228-22-IE   Denmark;Ireland;Netherlands;United Kingdom
      2016   Phase 4   EUCTR2016-003228-22-GB   Denmark;France;Ireland;Netherlands;United Kingdom
Teriparatide PEN injector
   University of Edinburgh
      2016   Phase 4   NCT03735537   Ireland;United Kingdom
Tranexamic acid
   Assiut University
      2022   -   NCT05321199   Egypt
UX143, BPS804
   Ultragenyx Pharmaceutical Inc.
      2023   Phase 2;Phase 3   EUCTR2021-006597-23-PT   Argentina;Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Portugal;Türkiye;United Kingdom;United States
      2023   Phase 2;Phase 3   EUCTR2021-006597-23-PL   Argentina;Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Portugal;Türkiye;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2021-006597-23-FR   Argentina;Australia;Canada;Denmark;France;Germany;Italy;Poland;Portugal;United Kingdom;United States
Vari
   AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
      2005   -   EUCTR2004-005275-42-IT   Italy
Vitamin D
   Amgen
      2021   Phase 1   NCT04545554   Austria;Germany;Greece;Hungary;Italy;Spain;Turkey;United States
   Louis-Nicolas Veilleux Ph.D.
      2012   Phase 4   NCT01713231   Canada
   Ultragenyx Pharmaceutical Inc
      2017   Phase 2   NCT03118570   Canada;Denmark;France;United Kingdom;United States
Water
   Ito Nobuaki
      2023   Phase 2   JPRN-jRCTs031220726   -
Xgeva
   AMGEN INC.
      2019   Phase 3   EUCTR2018-000550-21-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
   Amgen Inc
      2020   Phase 3   EUCTR2018-000550-21-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-000550-21-CZ   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-000550-21-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000550-21-GB   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000550-21-ES   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000550-21-PL   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000550-21-HU   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2018-000550-21-FR   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2018-000550-21-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
   Amgen Inc.
      2015   Phase 3   EUCTR2014-000184-40-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      -   -   EUCTR2014-000184-40-Outside-EU/EEA   Australia;Canada;United States
   Amgen, Inc.
      2020   Phase 3   EUCTR2014-000184-40-PL   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-000184-40-GB   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000184-40-HU   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000184-40-ES   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000184-40-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000184-40-CZ   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Hungary;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2014-000184-40-FR   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2014-000184-40-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
Xgeva - 120 MG - soluzione iniettabile - USO sottocutaneo - flaconcino (vetro) - 1.7 ML 4 flaconcini
   AMGEN INC.
      -   Phase 3   EUCTR2014-000184-40-IT   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
ZOL446
   Novartis Pharma AG
      2005   -   EUCTR2004-001666-40-HU   Hungary;United Kingdom
      2005   -   EUCTR2004-001666-40-GB   Hungary;United Kingdom
      -   Phase 2   EUCTR2004-001666-40-BE   Belgium;Hungary;United Kingdom
Zoledronic acid
   Assiut University
      2017   -   NCT03169192   Egypt
   Novartis Pharma AG
      2005   -   EUCTR2004-001666-40-HU   Hungary;United Kingdom
      2005   -   EUCTR2004-001666-40-GB   Hungary;United Kingdom
      -   Phase 2   EUCTR2004-001666-40-BE   Belgium;Hungary;United Kingdom
   Novartis Pharmaceuticals
      2004   Phase 2   NCT00131118   United States
      2003   Phase 2   NCT00063479   Germany;United States
   Schriners Hospitals for Children
      2012   Phase 3   EUCTR2011-000745-21-BE   Belgium;Canada;United States
   Shriners Hospitals for Children
      2007   Phase 3   NCT00982124   Canada
   Ultragenyx Pharmaceutical Inc
      2017   Phase 2   NCT03118570   Canada;Denmark;France;United Kingdom;United States
   University of Aarhus
      2012   Phase 2   NCT01679080   Denmark
   University of Edinburgh
      2022   Phase 4   EUCTR2016-003228-22-DK   Denmark;Ireland;Netherlands;United Kingdom
      2021   Phase 4   EUCTR2016-003228-22-NL   Denmark;France;Ireland;Netherlands;United Kingdom
      2017   Phase 4   EUCTR2016-003228-22-IE   Denmark;Ireland;Netherlands;United Kingdom
      2016   Phase 4   NCT03735537   Ireland;United Kingdom
      2016   Phase 4   EUCTR2016-003228-22-GB   Denmark;France;Ireland;Netherlands;United Kingdom
Zoledronic acid kern pharma 4 MG/100 ML solution FOR infusion, generic medicinal product
   Mereo BioPharma 3 Ltd.
      2017   Phase 2   EUCTR2016-005096-27-DK   Canada;Denmark;France;United Kingdom;United States
   Mereo Biopharma 3 Ltd.
      2017   Phase 2   EUCTR2016-005096-27-GB   Canada;Denmark;France;United Kingdom;United States
Zoledronic acid kern pharma 4 MG/100 ML solution FOR infusion,generic medicinal product
   Mereo BioPharma 3 Ltd.
      2017   Phase 2   EUCTR2016-005096-27-DK   Canada;Denmark;France;United Kingdom;United States
Zometa
   Novartis
      -   -   EUCTR2015-003539-37-Outside-EU/EEA   United States